| 词条 | Paroxetine | ||||||||||||||||||||||||||||||||
| 释义 |
| Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 417832251 | IUPAC_name = (3S,4R)-3-[(2H-1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine | image = Paroxetine-2D-skeletal.svg | image2 = Paroxetine-3D-balls.png | tradename = Paxil, Seroxat, others | Drugs.com = {{drugs.com|monograph|paroxetine-hydrochloride}} | MedlinePlus = a698032 | licence_EU = | licence_US = Paroxetine | pregnancy_AU = D | pregnancy_US = D | legal_AU = S4 | legal_CA = Rx-only | legal_UK = POM | legal_US = Rx-only | legal_status = Rx-only | routes_of_administration = By mouth | bioavailability = Extensively absorbed from the GI tract, but extensive first-pass metabolism in the liver[1][2][3][4] | protein_bound = 93–95%[1][2][3] | metabolism = Extensive, hepatic (mostly CYP2D6-mediated)[1][2][3] | elimination_half-life = 21 hours[1][2][3] | excretion = Renal (64%; 2% unchanged and 62% as metabolites), Faecal (36%; <1% unchanged)[1][2][3] | IUPHAR_ligand = 4790 | CAS_number_Ref = {{cascite|correct|??}} | CAS_number = 61869-08-7 | ATC_prefix = N06 | ATC_suffix = AB05 | PubChem = 43815 | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = DB00715 | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ChemSpiderID = 39888 | UNII_Ref = {{fdacite|correct|FDA}} | UNII = 41VRH5220H | KEGG_Ref = {{keggcite|correct|kegg}} | KEGG = D02362 | ChEBI_Ref = {{ebicite|changed|EBI}} | ChEBI = 7936 | ChEMBL_Ref = {{ebicite|correct|EBI}} | ChEMBL = 490 | C=19 | H=20 | F=1 | N=1 | O=3 | molecular_weight = 329.3 g/mol | smiles = c1cc(ccc1[C@@H]2CCNC[C@H]2COc3ccc4c(c3)OCO4)F | StdInChI_Ref = {{stdinchicite|correct|chemspider}} | StdInChI = 1S/C19H20FNO3/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18/h1-6,9,14,17,21H,7-8,10-12H2/t14-,17-/m0/s1 | StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | StdInChIKey = AHOUBRCZNHFOSL-YOEHRIQHSA-N |drug_name=|alt=|caption=|type=|pregnancy_category=}}Paroxetine, sold under the brand names Paxil and Seroxat among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class.[5] It is used to treat major depressive disorder, obsessive-compulsive disorder, panic disorder, social anxiety disorder, posttraumatic stress disorder, generalized anxiety disorder and premenstrual dysphoric disorder.[5] It has also been used in the treatment of hot flashes due to menopause and premature ejaculation.[6][5] It is taken by mouth.[5] Common side effects include drowsiness, dry mouth, loss of appetite, sweating, trouble sleeping, and sexual dysfunction.[5] Serious side effects may include suicide in those under the age of 25, serotonin syndrome, and mania.[5] While rate of side effects appear similar compared to other SSRIs and SNRIs, antidepressant discontinuation syndromes may occur more often.[7][8] Use in pregnancy is not recommended while use during breastfeeding is relatively safe.[9] It believed to work by blocking the re-uptake of the chemical serotonin by neurons in the brain.[5] Paroxetine was approved for medical use in the United States in 1992 and initially sold by GlaxoSmithKline.[5][10] It is currently avaliable as a generic medication.[11] A month supply in the United Kingdom costs the NHS about 1.10 £ per month as of 2019.[11] In the United States the wholesale cost of this amount is about 2.40 USD.[12] In 2016, it was the 64th most prescribed medication in the United States, with more than 12 million prescriptions.[13] The United States Department of Justice fined GlaxoSmithKline $3 billion in 2012, for withholding data, unlawfully promoting use in those under 18, and preparing an article that misleadingly reported the effects of paroxetine in adolescent with depression following its clinical trial study 329.[14][15][16] Medical usesParoxetine is primarily used to treat major depressive disorder, obsessive-compulsive disorder, post-traumatic stress disorder, social anxiety disorder, panic disorder, agoraphobia, generalized anxiety disorder, premenstrual dysphoric disorder and menopausal hot flashes.[17][18] DepressionA variety of meta analyses have been conducted to evaluate the efficacy of paroxetine in depression. They have variously concluded that paroxetine is superior or equivalent to placebo and that it is equivalent or inferior to other antidepressants.[19][20][21] Despite this, there was no clear evidence that paroxetine was better or worse compared with other antidepressants at increasing response to treatment at any time point.[22] Anxiety disordersParoxetine was the first antidepressant approved in the United States for the treatment of panic disorder.[23]{{page needed|date=January 2017}} Several studies have concluded that paroxetine is superior to placebo in the treatment of panic disorder.[24][25] Paroxetine has demonstrated efficacy for the treatment of social anxiety disorder in adults and children.[26][27] It is also beneficial for people with co-occurring social anxiety disorder and alcohol use disorder.[28] It appears to be similar to a number of other SSRIs.[29] Paroxetine is used in the treatment of obsessive-compulsive disorder.[30] Comparative efficacy of paroxetine is equivalent to that of clomipramine and venlafaxine.[31][32] Paroxetine is also effective for children with obsessive-compulsive disorder.[33] Paroxetine is approved for treatment of PTSD in the United States, Japan and Europe.[34][35][36] In the United States it is approved for short term use.[35] Paroxetine has also FDA approval for Generalized anxiety disorder.[37] Menopausal hot flashesOn June 28, 2013, the U.S. Food and Drug Administration approved low-dose paroxetine for the treatment of moderate-to-severe vasomotor symptoms such as hot flashes and night sweats associated with menopause.[6] At the low dose used for menopausal hot flashes, side effects are similar to placebo and dose tapering is not required for discontinuation.[38] Adverse effects{{See also|List of adverse effects of paroxetine}}Common side effects include drowsiness, dry mouth, loss of appetite, sweating, trouble sleeping, and sexual dysfunction.[5] Serious side effects may include suicide in those under the age of 25, serotonin syndrome, and mania.[5] While rate of side effects appear similar compared to other SSRIs and SNRIs, antidepressant discontinuation syndromes may occur more often.[39][40] Use in pregnancy is not recommended while use during breastfeeding is relatively safe.[9] Paroxetine shares many of the common adverse effects of SSRIs, including (with the corresponding rates seen in people treated with placebo in parentheses): nausea 26% (9%), diarrhea 12% (8%), constipation 14% (9%), dry mouth 18% (12%), somnolence 23% (9%), insomnia 13% (6%), headache 18% (17%), hypomania 1% (0.3%), blurred vision 4%(1%), loss of appetite 6% (2%), nervousness 5% (3%), paraesthesia 4% (2%), dizziness 13% (6%), asthenia (weakness; 15% (6%)), tremor 8% (2%), sweating 11% (2%), and sexual dysfunction (≥10% incidence).[4] Most of these adverse effects are transient and go away with continued treatment. Central and peripheral 5-HT3 receptor stimulation is believed to result in the gastrointestinal effects observed with SSRI treatment.[67] Compared to other SSRIs, it has a lower incidence of diarrhea, a higher incidence of anticholinergic effects (e.g., dry mouth, constipation, blurred vision, etc.), sedation/somnolence/drowsiness, sexual side effects, and weight gain.[68] Due to reports of adverse withdrawal reactions upon terminating treatment, the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency recommends gradually reducing over several weeks or months if the decision to withdraw is made.[41] See also Discontinuation syndrome (withdrawal). Mania or hypomania may occur in 1% of patients with depression and up to 12% of patients with bipolar disorder.[42] This side effect can occur in individuals with no history of mania but it may be more likely to occur in those with bipolar or with a family history of mania.[43]SuicideLike other antidepressants, paroxetine may increase the risk of suicidal thinking and behaviour in children and adolescents.[44][45] The FDA conducted a statistical analysis of paroxetine clinical trials in children and adolescents in 2004 and found an increase in suicidality and ideation as compared to placebo, which was observed in trials for both depression and anxiety disorders.[46] In 2015 a paper published in The BMJ that reanalysed the original case notes argued that in Study 329,[47] assessing paroxetine and imipramine against placebo in adolescents with depression, the incidence of suicidal behavior had been under-reported and the efficacy exaggerated for paroxetine.[48] Sexual dysfunction{{See also|Selective serotonin reuptake inhibitor#Sexual dysfunction}}Sexual dysfunction, including loss of libido, anorgasmia, lack of vaginal lubrication, and erectile dysfunction, is one of the most commonly encountered adverse effects of treatment with paroxetine and other SSRIs. While early clinical trials suggested a relatively low rate of sexual dysfunction, more recent studies in which the investigator actively inquires about sexual problems suggest that the incidence is higher than 70%.[49] Symptoms of sexual dysfunction have been reported to persist after discontinuing SSRIs, although this is thought to be occasional.[50][51][52] PregnancyThe American College of Obstetricians and Gynecologists recommends that for pregnant women and women planning to become pregnant, "treatment with all SSRIs or selective norepinephrine reuptake inhibitors or both during pregnancy be individualized and paroxetine use among pregnant women or women planning to become pregnant be avoided, if possible".[81] It may be associated with a slightly increased risk of birth defects.[53][54] According to the prescribing information, "epidemiological studies have shown that infants born to women who had first trimester paroxetine exposure had an increased risk of cardiovascular malformations, primarily ventricular and atrial septal defects (VSDs and ASDs). In general, septal defects range from those that are symptomatic and may require surgery to those that are asymptomatic and may resolve spontaneously. If a patient becomes pregnant while taking paroxetine, she should be advised of the potential harm to the fetus. Unless the benefits of paroxetine to the mother justify continuing treatment, consideration should be given to either discontinuing paroxetine therapy or switching to another antidepressant."[55] These conclusions are supported by multiple systematic reviews and meta-analyses that found that, on average, the use of paroxetine during pregnancy is associated with about 1.5–1.7-fold increase in congenital birth defects, in particular, heart defects.[56][57][58][59][60] Discontinuation syndrome{{See also|SSRI discontinuation syndrome}}Many psychoactive medications can cause withdrawal symptoms upon discontinuation from administration. Evidence has shown that paroxetine has among the highest incidence rates and severity of withdrawal syndrome of any medication of its class.[61] Common withdrawal symptoms for paroxetine include nausea, dizziness, lightheadedness and vertigo; insomnia, nightmares and vivid dreams; feelings of electricity in the body, as well as rebound depression and anxiety. Liquid formulation of paroxetine is available and allows a very gradual decrease of the dose, which may prevent discontinuation syndrome. Another recommendation is to temporarily switch to fluoxetine, which has a longer half-life and thus decreases the severity of discontinuation syndrome.[62][63][64] OverdoseAcute overdosage is often manifested by emesis, lethargy, ataxia, tachycardia, and seizures. Plasma, serum, or blood concentrations of paroxetine may be measured to monitor therapeutic administration, confirm a diagnosis of poisoning in hospitalized patients or to aid in the medicolegal investigation of fatalities. Plasma paroxetine concentrations are generally in a range of 40–400 μg/L in persons receiving daily therapeutic doses and 200–2,000 μg/L in poisoned patients. Postmortem blood levels have ranged from 1–4 mg/L in acute lethal overdose situations.[65][66] Along with the other SSRIs, sertraline and fluoxetine, paroxetine is considered a low-risk drug in cases of overdose.[67] InteractionsInteractions with other drugs acting on the serotonin system or impairing the metabolism of serotonin may increase the risk of Serotonin Syndrome or Neuroleptic Malignant Syndrome (NMS)-like reaction. Such reactions have been observed with SNRIs and SSRIs alone, but particularly with concurrent use of triptans, MAO inhibitors, antipsychotics, or other dopamine antagonists. Paroxetine has been shown to interact with statins, resulting in increased blood glucose levels and potentially diabetes. This was demonstrated in a retrospective study.[68] The prescribing information states that paroxetine should "not be used in combination with an MAOI (including linezolid, an antibiotic which is a reversible non-selective MAOI), or within 14 days of discontinuing treatment with an MAOI", and should not be used in combination with pimozide, thioridazine, tryptophan, or warfarin.[55] Paroxetine interacts with the following cytochrome P450 enzymes:[69][70]
PharmacologyPharmacodynamicsParoxetine is the most potent and one of the most specific selective serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibitors (SSRIs).[72] It also binds to the allosteric site of the serotonin transporter, similarly, but less potently, than escitalopram.[73] Paroxetine also inhibits the reuptake of norepinephrine to a lesser extent (<50 nmol/L).[74] Based on evidence from four weeks of administration in rats, the equivalent of 20 mg paroxetine taken once daily occupies approximately 88% of serotonin transporters in the prefrontal cortex.[70]
PharmacokineticsParoxetine is well-absorbed following oral administration.[70] It has an absolute bioavailability of about 50%, with evidence of a saturable first-pass effect.[78] When taken orally, it achieves maximum concentration in about 6–10 hours[70] and reaches steady-state in 7–14 days.[78] Paroxetine exhibits significant interindividual variations in volume of distribution and clearance.[78] Less than 2% of an oral dose is excreted in urine unchanged.[78] Paroxetine is a mechanism-based inhibitor of CYP2D6.[71][79] Society and cultureGlaxoSmithKline has paid substantial fines, paid settlements in class-action lawsuits, and become the subject of several highly critical books about its marketing of paroxetine, in particular the off-label marketing of paroxetine for children, the suppression of negative research results relating to its use in children, and allegations that it failed to warn consumers of substantial withdrawal effects associated with use of the drug.[14][15] Paroxetine was approved for medical use in the United States in 1992 and initially sold by GlaxoSmithKline.[5][80] It is currently avaliable as a generic medication.[11] A month supply in the United Kingdom costs the NHS about 1.10 £ per month as of 2019.[11] In the United States the wholesale cost of this amount is about 2.40 USD.[12] In 2016, it was the 64th most prescribed medication in the United States, with more than 12 million prescriptions.[81] The United States Department of Justice fined GlaxoSmithKline $3 billion in 2012, for withholding data, unlawfully promoting use in those under 18, and preparing an article that misleadingly reported the effects of paroxetine in adolescent with depression following its clinical trial study 329.[14][15][16]Withdrawal symptomsIn 2002 the U.S. FDA published a warning regarding "severe" discontinuation symptoms among those terminating paroxetine treatment, including paraesthesia, bad dreams, and dizziness. The Agency also warned of case reports describing agitation, sweating, and nausea. In connection with a Glaxo spokesperson's statement that withdrawal reactions occur only in 0.2% of patients and are "mild and short-lived", the International Federation of Pharmaceutical Manufacturers Associations said GSK had breached two of the Federation's codes of practice.[82] Paroxetine prescribing information posted at GlaxoSmithKline now acknowledges the occurrence of a discontinuation syndrome, including serious discontinuation symptoms.[55] Off-label marketing{{See also|Study 329}}In early 2004, GSK agreed to settle charges of consumer fraud for $2.5 million.[83] The legal discovery process also uncovered evidence of deliberate, systematic suppression of unfavorable Paxil research results. One of GSK's internal documents read, "It would be commercially unacceptable to include a statement that efficacy [in children] had not been demonstrated, as this would undermine the profile of paroxetine".[84] In 2012 the U.S. Justice Department announced that GSK agreed to plead guilty and pay a $3 billion fine, in part for promoting the use of Paxil for children.[16] MarketingOn 12 February 2016, the UK Competition and Markets Authority imposed record fines of £45 million on companies which were found to have infringed European Union and UK Competition law by entering into agreements to delay the market entry of generic versions of the drug in the UK. GlaxoSmithKline received the bulk of the fines, being fined £37,600,757. Other companies, which produce generics, were issued fines which collectively total £7,384,146. UK public health services are likely to claim damages for being overcharged in the period where the generic versions of the drug were illegally blocked from the market, as the generics are over 70% less expensive. GlaxoSmithKline may also face actions from other generics manufacturers who incurred loss as a result of the anticompetitive conduct.[85] On 18 April 2016, appeals were lodged with the Competition Appeal Tribunal by the companies which were fined.[86][87][88][89][90] SalesIn 2007, paroxetine was ranked 94th on the list of bestselling drugs, with over $1 billion in sales. In 2006, paroxetine was the fifth-most prescribed antidepressant in the U.S. retail market, with more than 19.7 million prescriptions.[91] In 2007, sales had dropped slightly to 18.1 million but paroxetine remained the fifth-most prescribed antidepressant in the U.S.[92][93] Trade namesTrade names include Aropax, Brisdelle, Deroxat, Paxil,[94] Pexeva, Paxtine, Paxetin, Paroxat, Paraxyl,[95] Sereupin, Daparox and Seroxat. ResearchSeveral studies have suggested that paroxetine can be used in the treatment of premature ejaculation. In particular, intravaginal ejaculation latency time (IELT) was found to increase with 6–13-fold, which was somewhat longer than the delay achieved by the treatment with other SSRIs (fluvoxamine, fluoxetine, sertraline, and citalopram).[96][97][98] However, paroxetine taken acutely ("on demand") 3–10 hours before coitus resulted only in a "clinically irrelevant and sexually unsatisfactory" 1.5-fold delay of ejaculation and was inferior to clomipramine, which induced a fourfold delay.[98] There is also evidence that paroxetine may be effective in the treatment of compulsive gambling[99] and hot flashes.[100] Benefits of paroxetine prescription for diabetic neuropathy[101] or chronic tension headache[102] are uncertain. Although the evidence is conflicting, paroxetine may be effective for the treatment of dysthymia, a chronic disorder involving depressive symptoms for most days of the year.[103] See also
References1. ^1 2 3 4 5 {{cite web|title=PRODUCT INFORMATION PAROXETINE SANDOZ 20mg FILM-COATED TABLETS|website=TGA eBusiness Services|author=Sandoz Pty Ltd|author-link=Sandoz|publisher=Therapeutic Goods Administration|date=18 January 2012|accessdate=22 November 2013|url=https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-03771-3|format=PDF}} 2. ^1 2 3 4 {{cite web|title=PAROXETINE (paroxetine hydrochloride hemihydrate) tablet, film coated|website=DailyMed|author=Mylan Institutional Inc.|author-link=Mylan|publisher=U.S. National Library of Medicine|date=January 2012|accessdate=22 November 2013|url=http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f235ee45-9517-45de-8df7-9a06fdb43380}} 3. ^1 2 3 4 {{cite web|title=Paroxetine 20 mg Tablets – Summary of Product Characteristics (SPC)|website=electronic Medicines Compendium|author=Sandoz Limited|author-link=Sandoz|publisher=Datapharm Ltd|date=21 March 2013|accessdate=22 November 2013|url=http://www.medicines.org.uk/emc/medicine/26634/SPC/Paroxetine+20+mg+Tablets/}} 4. ^1 {{cite web|title=Paxil, Paxil CR (paroxetine) dosing, indications, interactions, adverse effects, and more|website=Medscape Reference|publisher=WebMD|accessdate=22 November 2013|url=http://reference.medscape.com/drug/paxil-brisdelle-paroxetine-342959}} 5. ^1 2 3 4 5 6 7 8 9 10 {{cite web|url=https://www.drugs.com/monograph/paroxetine-hydrochloride.html|title=Paroxetine Hydrochloride Monograph for Professionals|website=Drugs.com|publisher=American Society of Health-System Pharmacists|language=en|accessdate=3 March 2019}} 6. ^1 {{cite press release|title=FDA approves the first non-hormonal treatment for hot flashes associated with menopause|first=Andrea |last=Fischer|publisher=Food and Drug Administration|date=June 28, 2013|url=http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm359030.htm|archive-url=https://web.archive.org/web/20170118091242/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm359030.htm |archive-date=January 18, 2017}} 7. ^{{Cite journal|title = SSRIs and SNRIs: A review of the Discontinuation Syndrome in Children and Adolescents|journal = Journal of the Canadian Academy of Child and Adolescent Psychiatry|date = February 2011 |issn = 1719-8429|pmc = 3024727|pmid = 21286371|pages = 60–67|volume = 20|issue = 1|first = Sheik|last = Hosenbocus|first2 = Raj|last2 = Chahal}} 8. ^{{cite journal |last1=Pae |first1=CU |last2=Patkar |first2=AA |title=Paroxetine: current status in psychiatry. |journal=Expert review of neurotherapeutics |date=February 2007 |volume=7 |issue=2 |pages=107–20 |doi=10.1586/14737175.7.2.107 |pmid=17286545}} 9. ^1 {{cite web |title=Paroxetine Pregnancy and Breastfeeding Warnings|url=https://www.drugs.com/pregnancy/paroxetine.html |website=Drugs.com |accessdate=3 March 2019 |language=en}} 10. ^{{cite book |last1=Administration |first1=Food and Drug |title=Approved Drug Products with Therapeutic Equivalence Evaluations - FDA Orange Book 31st Edition (2011): FDA Orange Book 31st Edition (2011) |date=2011 |publisher=DrugPatentWatch.com |isbn=9781934899816 |page=344 |url=https://books.google.ca/books?id=JDZ4DAAAQBAJ&pg=PR344 |language=en}} 11. ^1 2 3 {{cite book|title=British national formulary : BNF 76|date=2018|publisher=Pharmaceutical Press|isbn=9780857113382|pages=363|edition=76}} 12. ^1 {{cite web |title=NADAC as of 2019-02-27 |url=https://data.medicaid.gov/Drug-Pricing-and-Payment/NADAC-as-of-2019-02-27/s7c9-pfa6 |website=Centers for Medicare and Medicaid Services |accessdate=3 March 2019 |language=en}} 13. ^{{cite web |title=The Top 300 of 2019 |url=https://clincalc.com/DrugStats/Top300Drugs.aspx |website=clincalc.com |accessdate=22 December 2018}} 14. ^1 2 {{cite press release |url=http://www.justice.gov/opa/pr/2012/July/12-civ-842.html |title=GlaxoSmithKline to Plead Guilty and Pay $3 Billion to Resolve Fraud Allegations and Failure to Report Safety Data |publisher=United States Department of Justice, Office of Public Affairs |date=2 July 2012 |quote=The United States alleges that, among other things, GSK participated in preparing, publishing and distributing a misleading medical journal article that misreported that a clinical trial of Paxil demonstrated efficacy in the treatment of depression in patients under age 18, when the study failed to demonstrate efficacy. }} 15. ^1 2 {{cite court |url=http://www.justice.gov/sites/default/files/opa/legacy/2012/07/02/us-complaint.pdf |format=PDF |litigants=United States ex rel. Greg Thorpe, et al. v. GlaxoSmithKline PLC, and GlaxoSmithKline LLC |court=D. Mass. |date=26 October 2011 |pinpoint=pp. 3–19 }} 16. ^1 2 {{cite news |last1=Thomas |first1=Katie |last2=Schmidt |first2=Michael S. |url=https://www.nytimes.com/2012/07/03/business/glaxosmithkline-agrees-to-pay-3-billion-in-fraud-settlement.html |title=Glaxo Agrees to Pay $3 Billion in Fraud Settlement |newspaper=The New York Times |date=2 July 2012 }} 17. ^{{Cite journal|title = Paroxetine: an update of its use in psychiatric disorders in adults|journal = Drugs|date =March 2002|issn = 0012-6667|pmid = 11893234|pages = 655–703|volume = 62|issue = 4|first = Antona J.|last = Wagstaff|first2 = Susan M.|last2 = Cheer|first3 = Anna J.|last3 = Matheson|first4 = Douglas|last4 = Ormrod|first5 = Karen L.|last5 = Goa|doi=10.2165/00003495-200262040-00010 |subscription=yes }} 18. ^{{Cite journal|title = Paroxetine controlled release was effective and tolerable for treating menopausal hot flash symptoms in women|url = http://ebm.bmj.com/content/9/1/23.full|journal = Evidence Based Medicine|date = 2004-01-01|issn = 1473-6810|pages = 23|volume = 9|issue = 1|doi = 10.1136/ebm.9.1.23 |doi-access=free |first = Pamela|last = Lotke|first2 = Francisco|last2 = Garcia}} 19. ^{{cite journal |vauthors=Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H, Tansella M, Barbui C |display-authors=3 |title=Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis |journal=Lancet |volume=373 |issue=9665 |pages=746–58 |date=28 February 2009 |pmid=19185342 |doi=10.1016/S0140-6736(09)60046-5 |subscription=yes }} 20. ^{{cite journal |title=A Double-Blind Study of Paroxetine, Fluoxetine, and Placebo in Outpatients with Major Depression |url= |journal=Annals of Clinical Psychiatry |pages=145–150 |volume=10 |issue=4 |doi=10.3109/10401239809147030 |first=Maurizio |last=Fava |first2=Jay |last2=Amsterdam |first3=Joseph |last3=Deltito |first4=Carl |last4=Salzman |first5=Michael |last5=Schwaller |first6=David |last6=Dunner |date=December 1998 |pmid=9988054 }} 21. ^{{cite journal |title=The Efficacy of Paroxetine and Placebo in Treating Anxiety and Depression: A Meta-Analysis of Change on the Hamilton Rating Scales |journal=PLoS ONE |date=2014-08-27 |pmc=4146610 |pmid=25162656 |pages=e106337 |volume=9 |issue=8 |doi=10.1371/journal.pone.0106337 |first=Michael A. |last=Sugarman |first2=Amy M. |last2=Loree |first3=Boris B. |last3=Baltes |first4=Emily R. |last4=Grekin |first5=Irving |last5=Kirsch}} 22. ^{{cite journal |title=Paroxetine versus other anti-depressive agents for depression |journal=The Cochrane Database of Systematic Reviews |date=3 April 2014 |issue=4 |page=CD006531 |pmid=24696195 |issn=1465-1858 |doi=10.1002/14651858.cd006531.pub2 |doi-access=free |first=Marianna |last=Purgato |first2=Davide |last2=Papola |first3=Chiara |last3=Gastaldon |first4=Carlotta |last4=Trespidi |first5=Laura R |last5=Magni |first6=Carla |last6=Rizzo |first7=Toshi A |last7=Furukawa |first8=Norio |last8=Watanabe |first9=Andrea |last9=Cipriani|pmc=4176672 }} 23. ^{{cite book|title=Social Work Diagnosis in Contemporary Practice |last=Turner |first=Francis Joseph |year=2005 |publisher=Oxford University Press US|isbn=978-0-19-516878-5 }} 24. ^{{Cite journal|title = Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder|journal = The American Journal of Psychiatry|date = 1998-01-01|issn = 0002-953X|pmid = 9433336|pages = 36–42|volume = 155|issue = 1|doi = 10.1176/ajp.155.1.36 |doi-access=free |first = J. C.|last = Ballenger|first2 = D. E.|last2 = Wheadon|first3 = M.|last3 = Steiner|first4 = W.|last4 = Bushnell|first5 = I. P.|last5 = Gergel }} 25. ^{{Cite journal|title = The Efficacy of Paroxetine and Placebo in Treating Anxiety and Depression: A Meta-Analysis of Change on the Hamilton Rating Scales |journal = PLoS ONE|date = 2014-08-27|pmc = 4146610|pmid = 25162656|pages = e106337|volume = 9|issue = 8|doi = 10.1371/journal.pone.0106337|first = Michael A.|last = Sugarman|first2 = Amy M.|last2 = Loree|first3 = Boris B.|last3 = Baltes|first4 = Emily R.|last4 = Grekin|first5 = Irving|last5 = Kirsch}} 26. ^{{Cite journal|title = Paroxetine treatment of generalized social phobia (social anxiety disorder): A randomized controlled trial|url = |journal = JAMA|date = 1998-08-26|issn = 0098-7484|pages = 708–713|volume = 280|issue = 8|doi = 10.1001/jama.280.8.708 |doi-access=free |last = Stein MB|last2 = Liebowitz MR|last3 = Lydiard R|last4 = Pitts CD|last5 = Bushnell W|last6 = Gergel I|pmid=9728642}} 27. ^{{Cite journal|title = Paroxetine improves social anxiety disorder in children and adolescents|url = http://ebmh.bmj.com/content/8/2/43.full |journal = Evidence Based Mental Health|date = 2005-05-01|issn = 1468-960X|pmid = 15851806|pages = 43|volume = 8|issue = 2|doi = 10.1136/ebmh.8.2.43 |doi-access=free |first = Katharina|last = Manassis}} 28. ^{{Cite journal|title = Paroxetine for social anxiety and alcohol use in dual-diagnosed patients|journal = Depression and Anxiety|date = 2001-01-01|issn = 1520-6394|pages = 255–262|volume = 14|issue = 4|doi = 10.1002/da.1077|first = Carrie L.|last = Randall|first2 = Michael R.|last2 = Johnson|first3 = Angelica K.|last3 = Thevos|first4 = Susan C.|last4 = Sonne|first5 = Suzanne E.|last5 = Thomas|first6 = Shauna L.|last6 = Willard|first7 = Kathleen T.|last7 = Brady|first8 = Jonathan R. |last8=Davidson |pmid=11754136 }} 29. ^{{cite journal |last1=Blanco |first1=C |last2=Bragdon |first2=LB |last3=Schneier |first3=FR |last4=Liebowitz |first4=MR |title=The evidence-based pharmacotherapy of social anxiety disorder. |journal=The international journal of neuropsychopharmacology |date=February 2013 |volume=16 |issue=1 |pages=235–49 |doi=10.1017/S1461145712000119 |pmid=22436306|quote= There were no significant differences between the three SSRIs that had been tested in placebo-controlled studies: paroxetine; sertraline; fluvoxamine.}} 30. ^{{cite book |editor-first=Harry G. |editor-last=Brittain |last1=Germann|first1=David |last2=Ma|first2=George |last3=Han|first3=Feixue |last4=Tikhomirova|first4=Anna |chapter=Paroxetine hydrochloride |title=Profiles of drug substances, excipients, and related methodology |journal=Profiles of Drug Substances, Excipients, and Related Methodology |series=Analytical Profiles of Drug Substances and Excipients |date=2013|volume=38|pages=367–406|pmid=23668408|doi=10.1016/B978-0-12-407691-4.00008-3|isbn=978-0-12-407691-4 |subscription=yes}} 31. ^{{Cite journal|title = Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators|url = http://bjp.rcpsych.org/content/169/4/468 |url-access=subscription |journal = The British Journal of Psychiatry|date = 1996-10-01|issn = 0007-1250|pmid = 8894198|pages = 468–474|volume = 169|issue = 4|doi = 10.1192/bjp.169.4.468|first = J.|last = Zohar|first2 = R.|last2 = Judge}} 32. ^{{Cite journal|title = A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder|journal = Journal of Clinical Psychopharmacology|date = 2003-12-01|issn = 0271-0749|pmid = 14624187|pages = 568–575|volume = 23|issue = 6|doi = 10.1097/01.jcp.0000095342.32154.54|first = Damiaan|last = Denys|first2 = Nic|last2 = van der Wee|first3 = Harold J. G. M.|last3 = van Megen|first4 = Herman G. M.|last4 = Westenberg |subscription=yes }} 33. ^{{cite journal|last1=Ipser|first1=JC|last2=Stein|first2=DJ|last3=Hawkridge|first3=S|last4=Hoppe|first4=L|title=Pharmacotherapy for anxiety disorders in children and adolescents|journal=The Cochrane Database of Systematic Reviews|date=8 July 2009|issue=3|pages=CD005170|pmid=19588367|doi=10.1002/14651858.CD005170.pub2 |subscription=yes |pmc=3263391}} 34. ^{{cite journal |last1=Alexander |first1=W |title=Pharmacotherapy for Post-traumatic Stress Disorder In Combat Veterans: Focus on Antidepressants and Atypical Antipsychotic Agents. |journal=P & T : a peer-reviewed journal for formulary management |date=January 2012 |volume=37 |issue=1 |pages=32–8 |pmid=22346334}} 35. ^1 {{cite journal |last1=Ipser |first1=Jonathan C. |last2=Stein |first2=Dan J. |title=Evidence-based pharmacotherapy of post-traumatic stress disorder (PTSD) |journal=The International Journal of Neuropsychopharmacology |date=29 July 2011 |volume=15 |issue=06 |pages=825–840 |doi=10.1017/S1461145711001209}} 36. ^{{Cite web|url=http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=34488|title=Search results detail{{!}} Kusurino-Shiori(Drug information Sheet)|website=www.rad-ar.or.jp|access-date=2019-03-15}} 37. ^{{Cite journal|date=2001-05-18|title=FDA Approves Antidepressant For Generalized Anxiety Disorder|url=https://psychnews.psychiatryonline.org/doi/abs/10.1176/pn.36.10.0014b|journal=Psychiatric News|language=en|doi=10.1176/pn.36.10.0014b}} 38. ^{{cite journal|last1=Orleans|first1=Ronald J.|last2=Li|first2=Li|last3=Kim|first3=Myong-Jin|last4=Guo|first4=Jia|last5=Sobhan|first5=Mahboob|last6=Soule|first6=Lisa|last7=Joffe|first7=Hylton V.|title=FDA Approval of Paroxetine for Menopausal Hot Flushes|journal=New England Journal of Medicine|volume=370|issue=19|date=8 May 2014|pages=1777–1779|issn=0028-4793|doi=10.1056/NEJMp1402080|doi-access=free|pmid=24806158}} 39. ^{{Cite journal|last=Hosenbocus|first=Sheik|last2=Chahal|first2=Raj|date=February 2011|title=SSRIs and SNRIs: A review of the Discontinuation Syndrome in Children and Adolescents|journal=Journal of the Canadian Academy of Child and Adolescent Psychiatry|volume=20|issue=1|pages=60–67|issn=1719-8429|pmc=3024727|pmid=21286371}} 40. ^{{cite journal|last1=Pae|first1=CU|last2=Patkar|first2=AA|date=February 2007|title=Paroxetine: current status in psychiatry.|journal=Expert review of neurotherapeutics|volume=7|issue=2|pages=107–20|doi=10.1586/14737175.7.2.107|pmid=17286545}} 41. ^{{cite web|url=http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2009/11/WC500015202.pdf|format=PDF|publisher=European Medicines Agency|title=Press release, CHMP meeting on Paroxetine and other SSRIs|date=2004-12-09|accessdate=2007-08-24}} 42. ^{{cite web |url=http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020031s067,020710s031.pdf |title=www.accessdata.fda.gov |format= |website= |accessdate=}} 43. ^{{cite journal |vauthors=Morishita S, Arita S | title = Induction of mania in depression by paroxetine | journal = Hum Psychopharmacol | volume = 18 | issue = 7 | pages = 565–8 | date = October 2003 | pmid = 14533140 | doi = 10.1002/hup.531 }} 44. ^{{cite web |url=http://www.fda.gov/downloads/drugs/drugsafety/informationbydrugclass/UCM161646.pdf |title=www.fda.gov |format= |website= |accessdate=}} 45. ^{{cite web |url=http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2004/ucm108363.htm |title=FDA Launches a Multi-Pronged Strategy to Strengthen Safeguards for Children Treated With Antidepressant Medications |website= |accessdate=}} 46. ^{{cite web | url =http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4065b1-10-TAB08-Hammads-Review.pdf | title =Review and evaluation of clinical data: relationship between psychotropic drugs and pediatric suicidality | accessdate = 2009-01-27 | author = Hammad TA | date = 2004-08-16|format =PDF | website = Joint Meeting of the Psychopharmacologic Drugs Advisory Committee and Pediatric Advisory Committee. September 13–14, 2004. Briefing Information. | publisher = FDA| page = 30}} 47. ^{{cite journal | author = Keller MB | title = Efficacy of Paroxetine in the Treatment of Adolescent Major Depression: A Randomized, Controlled Trial | journal = J Am Acad Child Adolesc Psychiatry | volume = 40 | issue = 7 | pages = 762–772 | year = 2001 | pmid = 11437014 | doi = 10.1097/00004583-200107000-00010 |display-authors=etal}} 48. ^Le Noury, Joanna, et al. "Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence", BMJ, 351, 16 September 2015. {{doi|10.1136/bmj.h4320}} {{PMID|26376805}}{{pb}}Godlee, Fiona. "Study 329", BMJ, 351, 17 September 2015. {{doi|10.1136/bmj.h4973}}{{pb}}Doshi, Peter. "No correction, no retraction, no apology, no comment: paroxetine trial reanalysis raises questions about institutional responsibility", BMJ, 351, 16 September 2015. {{doi|10.1136/bmj.h4629}} {{PMID|26377109}}{{pb}}Henry, David; Fitzpatrick, Tiffany. "Liberating the data from clinical trials", BMJ, 351, 16 September 2015. {{doi|10.1136/bmj.h4601}} {{PMID|26377210}}{{pb}}Boseley, Sarah. [https://www.theguardian.com/science/2015/sep/16/seroxat-study-harmful-effects-young-people "Seroxat study under-reported harmful effects on young people, say scientists"], The Guardian, 16 September 2015. 49. ^{{cite journal |vauthors=Clark MS, Jansen K, Bresnahan M |title=Clinical inquiry: How do antidepressants affect sexual function? |journal=J Fam Pract |volume=62 |issue=11 |pages=660–1 |date=November 2013 |pmid=24288712 |doi= |url=}} 50. ^{{cite journal |vauthors=Csoka AB, Csoka A, Bahrick A, Mehtonen OP | title = Persistent sexual dysfunction after discontinuation of selective serotonin reuptake inhibitors | journal = The Journal of Sexual Medicine | volume = 5 | issue = 1 | pages = 227–33 | year = 2008 | pmid = 18173768 | doi = 10.1111/j.1743-6109.2007.00630.x }} 51. ^{{cite journal |vauthors=Csoka AB, Shipko S | title = Persistent sexual side effects after SSRI discontinuation | journal = Psychotherapy and Psychosomatics | volume = 75 | issue = 3 | pages = 187–8 | year = 2006 | pmid = 16636635 | doi = 10.1159/000091777 | url = http://www.mediafire.com/view/hn31cmg4n28bq3x/06_pssd_Csoka.pdf | accessdate = 30 January 2014 }} 52. ^http://pi.lilly.com/us/prozac.pdf Page 14. 53. ^1 {{cite journal |author=ACOG Committee on Obstetric Practice | title = ACOG Committee Opinion No. 354: Treatment with selective serotonin reuptake inhibitors during pregnancy | journal = Obstet Gynecol | volume = 108 | issue = 6 | pages = 1601–3 |date=December 2006 | pmid = 17138801 | doi = 10.1097/00006250-200612000-00058 |subscription=yes }} 54. ^{{cite journal|last1=Yonkers|first1=KA|last2=Blackwell|first2=KA|last3=Glover|first3=J|last4=Forray|first4=A|title=Antidepressant use in pregnant and postpartum women|journal=Annual Review of Clinical Psychology|date=2014|volume=10|pages=369–92|pmid=24313569|doi=10.1146/annurev-clinpsy-032813-153626|pmc=4138492}} 55. ^1 2 {{cite web|url=http://us.gsk.com/products/assets/us_paxil.pdf |archiveurl=https://www.webcitation.org/61Bq63bfe?url=http%3A%2F%2Fus.gsk.com%2Fproducts%2Fassets%2Fus_paxil.pdf |archivedate=2011-08-25 |format=PDF |title=PAXIL (paroxetine hydrochloride) Tablets and Oral Suspension: PRESCRIBING INFORMATION |date=August 2007 |accessdate=2007-08-14 |publisher=GlaxoSmithKline |location=Research Triangle Park, NC |deadurl=no |df= }} 56. ^{{cite journal | author = Thormahlen GM | title = Paroxetine use during pregnancy: is it safe? | journal = Ann Pharmacother | volume = 40 | issue = 10 | pages = 1834–7 | date = October 2006 | pmid = 16926304 | doi = 10.1345/aph.1H116 }} 57. ^{{cite journal | author = Way CM | title = Safety of newer antidepressants in pregnancy | journal = Pharmacotherapy | volume = 27 | issue = 4 | pages = 546–52 | year = 2007 | pmid = 17381382 | doi = 10.1592/phco.27.4.546 }} 58. ^{{cite journal |vauthors=Bellantuono C, Migliarese G, Gentile S | title = Serotonin reuptake inhibitors in pregnancy and the risk of major malformations: a systematic review | journal = Hum Psychopharmacol | volume = 22 | issue = 3 | pages = 121–8 | year = 2007 | pmid = 17397101 | doi = 10.1002/hup.836 }} 59. ^{{cite journal | author = Källén B | title = The safety of antidepressant drugs during pregnancy | journal = Expert Opin Drug Saf | volume = 6 | issue = 4 | pages = 357–70 | date = July 2007 | pmid = 17688379 | doi = 10.1517/14740338.6.4.357 }} 60. ^{{cite journal |vauthors=Bar-Oz B, Einarson T, Einarson A, Boskovic R, O'Brien L, Malm H, Bérard A, Koren G | title = Paroxetine and congenital malformations: meta-Analysis and consideration of potential confounding factors | journal = Clin Ther | volume = 29 | issue = 5 | pages = 918–26 | date = May 2007 | pmid = 17697910 | doi = 10.1016/j.clinthera.2007.05.003 }} 61. ^{{cite journal |vauthors=Fava GA, Gatti A, Belaise C, Guidi J, Offidani E |title=Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review |journal=Psychother Psychosom |volume=84 |issue=2 |pages=72–81 |date=2015 |pmid=25721705 |doi=10.1159/000370338 |url=}} 62. ^{{cite journal |last=Haddad |first=Peter M. |name-list-format=vanc |title = Antidepressant discontinuation syndromes|journal = Drug Saf|volume = 24|issue = 3|pages = 183–97|date=March 2001|pmid = 11347722|doi = 10.2165/00002018-200124030-00003 |subscription=yes }} 63. ^{{cite journal |last1=Haddad |first1=Peter M. |last2=Anderson |first2=Ian M. |name-list-format=vanc |date=November 2007 |title=Recognising and managing antidepressant discontinuation symptoms|journal=Advances in Psychiatric Treatment |volume=13 |issue=6|pages=447–457|doi=10.1192/apt.bp.105.001966 |doi-access=free |url=http://apt.rcpsych.org/content/13/6/447.full }} 64. ^{{cite web |url=http://www.benzo.org.uk/healy.htm |title=Dependence on Antidepressants & Halting SSRIs |first=David |last=Healy |website=benzo.org.uk |access-date=2013-04-23 }} 65. ^{{cite journal |vauthors=Goeringer KE, Raymon L, Christian GD, Logan BK | title = Postmortem forensic toxicology of selective serotonin reuptake inhibitors: a review of pharmacology and report of 168 cases | journal = J. Forensic Sci. | volume = 45 | issue = 3 | pages = 633–48 | date = May 2000 | pmid = 10855970 }} 66. ^R. Baselt,Disposition of Toxic Drugs and Chemicals in Man, 8th edition, Biomedical Publications, Foster City, CA, 2008, pp. 1190–1193. 67. ^{{cite journal |vauthors=White N, Litovitz T, Clancy C | title = Suicidal antidepressant overdoses: a comparative analysis by antidepressant type | journal = Journal of Medical Toxicology | volume = 4 | issue = 4 | pages = 238–250 | date = December 2008 | pmid = 19031375 | pmc = 3550116 | doi = 10.1007/BF03161207 }} 68. ^{{cite journal|last1=Andrade|first1=C|title=Selective serotonin reuptake inhibitor drug interactions in patients receiving statins|journal=The Journal of Clinical Psychiatry|date=February 2014|volume=75|issue=2|pages=e95–9|pmid=24602259|url=http://www.psychiatrist.com/jcp/article/Pages/2014/v75n02/v75n0201.aspx|doi=10.4088/jcp.13f08941}} 69. ^1 2 {{cite book | title = Pharmacotherapy of Depression | year = 2011 | doi = 10.1007/978-1-60327-435-7 | publisher = Humana Press | isbn = 978-1-60327-434-0 | work = SpringerLink | edition = 2nd | location = New York, NY |editor1=Ciraulo, DA |editor2=Shader, RI }} 70. ^1 2 3 4 {{cite journal|last1=Sanchez|first1=C|last2=Reines|first2=EH|last3=Montgomery|first3=SA|title=A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike?|journal=International Clinical Psychopharmacology|date=July 2014|volume=29|issue=4|pages=185–96|doi=10.1097/YIC.0000000000000023|pmid=24424469|pmc=4047306}} 71. ^1 {{cite journal|last1=Stepan|first1=Antonia F.|last2=Mascitti|first2=Vincent|last3=Beaumont|first3=Kevin|last4=Kalgutkar|first4=Amit S.|title=Metabolism-guided drug design|journal=MedChemComm|date=2013|volume=4|issue=4|pages=631|doi=10.1039/C2MD20317K|url=http://pubs.rsc.org/en/content/articlelanding/2013/md/c2md20317k}} 72. ^{{cite journal |vauthors=Mellerup ET, Plenge P | title = High affinity binding of 3H-paroxetine and 3H-imipramine to rat neuronal membranes | journal = Psychopharmacology | volume = 89 | issue = 4 | pages = 436–9 | date = July 1986 | pmid = 2944152 | doi = 10.1007/BF02412117 | url = http://www.springerlink.com/content/5888x32v705t336r/ }} 73. ^{{cite journal |vauthors=Mansari ME, Wiborg O, Mnie-Filali O, Benturquia N, Sánchez C, Haddjeri N | title = Allosteric modulation of the effect of escitalopram, paroxetine and fluoxetine: in-vitro and in-vivo studies | journal = The International Journal of Neuropsychopharmacology | volume = 10 | issue = 1 | pages = 31–40 | date = February 2007 | pmid = 16448580 | doi = 10.1017/S1461145705006462 }} 74. ^{{Cite journal|title = [Second generation SSRIS: human monoamine transporter binding profile of escitalopram and R-fluoxetine]|journal = L'Encéphale|date = 2002-08-01|issn = 0013-7006|pmid = 12232544|pages = 350–355|volume = 28|issue = 4|first = J. M.|last = Owens|first2 = D. L.|last2 = Knight|first3 = C. B.|last3 = Nemeroff}} 75. ^{{cite journal|last1=Owens|first1=MJ|last2=Knight|first2=DL|last3=Nemeroff|first3=CB|title=Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine|journal=Biological Psychiatry|date=1 September 2001|volume=50|issue=5|pages=345–50|pmid=11543737|doi=10.1016/s0006-3223(01)01145-3}} 76. ^{{cite web|title=PDSP Ki Database |website=Psychoactive Drug Screening Program (PDSP) |author1=Roth, BL |author2=Driscol, J |url=http://pdsp.med.unc.edu/pdsp.php |publisher=University of North Carolina at Chapel Hill and the United States National Institute of Mental Health |accessdate=22 November 2013 |date=12 January 2011 |deadurl=yes |archiveurl=https://web.archive.org/web/20131108013656/http://pdsp.med.unc.edu/pdsp.php |archivedate=November 8, 2013 }} 77. ^1 {{cite book |author1=Brunton, L |author2=Chabner, B |author3=Knollman, B | title = Goodman and Gilman's The Pharmacological Basis of Therapeutics | year = 2010 | publisher = McGraw-Hill Professional | isbn = 978-0-07-162442-8 | edition = 12th | location = New York }} 78. ^1 2 3 {{cite journal|last1=Kaye|first1=CM|last2=Haddock|first2=RE|last3=Langley|first3=PF|last4=Mellows|first4=G|last5=Tasker|first5=TC|last6=Zussman|first6=BD|last7=Greb|first7=WH|title=A review of the metabolism and pharmacokinetics of paroxetine in man|journal=Acta Psychiatrica Scandinavica. Supplementum|date=1989|volume=350|pages=60–75|pmid=2530793}} 79. ^1 {{cite journal|last1=Jornil|first1=J|last2=Jensen|first2=KG|last3=Larsen|first3=F|last4=Linnet|first4=K|title=Identification of cytochrome P450 isoforms involved in the metabolism of paroxetine and estimation of their importance for human paroxetine metabolism using a population-based simulator|journal=Drug Metabolism and Disposition|date=March 2010|volume=38|issue=3|pages=376–85|doi=10.1124/dmd.109.030551|pmid=20007670}} 80. ^{{cite book|url=https://books.google.ca/books?id=JDZ4DAAAQBAJ&pg=PR344|title=Approved Drug Products with Therapeutic Equivalence Evaluations - FDA Orange Book 31st Edition (2011): FDA Orange Book 31st Edition (2011)|last1=Administration|first1=Food and Drug|date=2011|publisher=DrugPatentWatch.com|isbn=9781934899816|page=344|language=en}} 81. ^{{cite web|url=https://clincalc.com/DrugStats/Top300Drugs.aspx|title=The Top 300 of 2019|website=clincalc.com|accessdate=22 December 2018}} 82. ^{{cite journal |author = Tonks A|title = Withdrawal from paroxetine can be severe, warns FDA|journal = BMJ|volume = 324|issue = 7332|page = 260|date = February 2002|pmid = 11823353|pmc = 1122195|doi = 10.1136/bmj.324.7332.260}} 83. ^{{cite news |author=Angell M |authorlink=Marcia Angell |title=Drug Companies & Doctors: A Story of Corruption|newspaper=New York Review of Books |volume=56 |issue=1 |date=15 January 2009 }} 84. ^{{cite journal |vauthors=Kondro W, Sibbald B | title = Drug company experts advised staff to withhold data about SSRI use in children | journal = CMAJ | volume = 170 | issue = 5 | page = 783 | date = March 2004 | pmid = 14993169 | pmc = 343848 | doi = 10.1503/cmaj.1040213 }} 85. ^{{cite web | url=https://www.gov.uk/government/news/cma-fines-pharma-companies-45-million | title=CMA fines pharma companies £45 million}} 86. ^http://www.catribunal.org.uk/files/1252_GlaxoSmithKline_Summary_180416.pdf 87. ^http://www.catribunal.org.uk/files/1251_Generics_Summary_180416.pdf 88. ^http://www.catribunal.org.uk/files/1253_Xellia_Summary_180416.pdf 89. ^http://www.catribunal.org.uk/files/1255_Merck_Summary_180416.pdf 90. ^http://www.catribunal.org.uk/files/1254_Actavis_Summary_180416.pdf 91. ^The paroxetine prescriptions were calculated as a total of prescriptions for Paxil CR and generic paroxetine using data from the charts for generic and brand-name drugs.{{cite web | title = Top 200 generic drugs by units in 2006. Top 200 brand-name drugs by units| website = Drug Topics, Mar 5, 2007| url = http://www.drugtopics.com/drugtopics/article/articleDetail.jsp?id=407652| accessdate = 2007-04-08 }} 92. ^The paroxetine prescriptions were calculated as a total of prescriptions for Paxil CR and generic paroxetine using data from the charts for generic and brand-name drugs.{{cite web | title = Top 200 generic drugs by units in 2007| website = Drug Topics|date= February 18, 2008 | url =http://drugtopics.modernmedicine.com/drugtopics/Top200Drugs/ArticleStandard/article/detail/491194| archiveurl =https://web.archive.org/web/20090718184023/http://drugtopics.modernmedicine.com/drugtopics/Top200Drugs/ArticleStandard/article/detail/491194| archivedate =2009-07-18| accessdate = 2008-10-23}} 93. ^{{cite web | title = Top 200 brand drugs by units in 2007 | website = Drug Topics, Feb 18, 2008 | url =http://drugtopics.modernmedicine.com/drugtopics/PharmacyFactsAndFigures/ArticleStandard/article/detail/491210| archiveurl =https://web.archive.org/web/20090629042030/http://drugtopics.modernmedicine.com/drugtopics/PharmacyFactsAndFigures/ArticleStandard/article/detail/491210| archivedate =2009-06-29| accessdate = 2008-10-23}} 94. ^{{cite book | title=Dictionary of Psychology (Second Edition) | publisher=Oxford University Press | author=Coleman, Andrew | year=2006 | pages=552}} 95. ^{{cite book | title=Dictionary of Psychology (Second Edition) | publisher=Oxford University Press | author=Coleman, Andrew | year=2006 | pages=161}} 96. ^{{cite journal |vauthors=Waldinger MD, Hengeveld MW, Zwinderman AH, Olivier B | title = Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline | journal = Journal of Clinical Psychopharmacology | volume = 18 | issue = 4 | pages = 274–81 | date = August 1998 | pmid = 9690692 | doi = 10.1097/00004714-199808000-00004 }} 97. ^{{cite journal |vauthors=Waldinger MD, Zwinderman AH, Olivier B | title = SSRIs and ejaculation: a double-blind, randomized, fixed-dose study with paroxetine and citalopram | journal = Journal of Clinical Psychopharmacology | volume = 21 | issue = 6 | pages = 556–60 | year = 2001 | pmid = 11763001 | doi = 10.1097/00004714-200112000-00003 }} 98. ^1 {{cite journal |vauthors=Waldinger MD, Zwinderman AH, Olivier B | title = On-demand treatment of premature ejaculation with clomipramine and paroxetine: a randomized, double-blind fixed-dose study with stopwatch assessment | journal = Eur. Urol. | volume = 46 | issue = 4 | pages = 510–5; discussion 516 | year = 2004 | pmid = 15363569 | doi = 10.1016/j.eururo.2004.05.005 }} 99. ^{{cite journal |vauthors=Kim SW, Grant JE, Adson DE, Shin YC, Zaninelli R | title = A double-blind placebo-controlled study of the efficacy and safety of paroxetine in the treatment of pathological gambling | journal = Journal of Clinical Psychiatry | volume = 63 | issue = 6 | pages = 501–7 | year = 2002 | pmid = 12088161 | doi = 10.4088/JCP.v63n0606 }} 100. ^{{cite journal |vauthors=Weitzner MA, Moncello J, Jacobsen PB, Minton S | title = A pilot trial of paroxetine for the treatment of hot flashes and associated symptoms in women with breast cancer | journal = Journal of Pain and Symptom Management | volume = 23 | issue = 4 | pages = 337–345 | year = 2002 | pmid = 11997203 | doi = 10.1016/S0885-3924(02)00379-2 }} 101. ^{{cite journal |vauthors=Sindrup SH, Gram LF, Brøsen K, Eshøj O, Mogensen EF | title = The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms | journal = Pain | volume = 42 | issue = 2 | pages = 135–144 | year = 1999 | pmid = 2147235 | doi = 10.1016/0304-3959(90)91157-E }} 102. ^{{cite journal |vauthors=Langemark M, Olesen J | title = Sulpiride and paroxetine in the treatment of chronic tension-type headache. An explanatory double-blind trial | journal = Headache | volume = 34 | issue = 1 | pages = 20–4 | year = 1994 | pmid = 8132436 | doi = 10.1111/j.1526-4610.1994.hed3401020.x }} 103. ^{{cite journal |vauthors=Gartlehner G, Gaynes BN, Hansen RA, Thieda P, DeVeaugh-Geiss A, Krebs EE, Moore CG, Morgan L, Lohr KN | title = Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians | journal = Ann. Intern. Med. | volume = 149 | issue = 10 | pages = 734–50 | date = November 2008 | pmid = 19017592 | doi = 10.7326/0003-4819-149-10-200811180-00008 }} External links{{Commons category}}
9 : Selective serotonin reuptake inhibitors|Muscarinic antagonists|Benzodioxoles|Piperidines|Fluoroarenes|Phenol ethers|GlaxoSmithKline brands|Psychiatry controversies|RTT |
||||||||||||||||||||||||||||||||
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。